Clinical trials using Omicron-specific vaccinations are now underway, but no data on human participants has been released. Meanwhile, the FDA wants to move COVID vaccines to a flu like model.
Officials from the Food and Drug Administration (FDA) have suggested a future paradigm for producing new COVID-19 vaccinations based on the method used to produce influenza vaccines.
The existing COVID-19 vaccinations, which are based on a virus strain that is now many generations old, "may need to be updated at some point to ensure the high level of efficacy demonstrated in the early vaccine clinical trials," according to the FDA.
One source of concern is the constant emergence of new SARS-CoV-2 strains, some of which circumvent vaccine protection better than others. COVID-19 is caused by SARS-CoV-2, commonly known as coronavirus.
The vaccines provides almost zero protection against infection by Omicron, the variant that is currently prevalent in the United States, yet they have ...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
